The company said it was intentional, probably because of the reason you mentioned: “In a statement to Fortune, Novo Nordisk said there was no mistake regarding its patent maintenance fee in Canada.”

I still don’t get that though: is that worth losing exclusivity over?

I guess they think some other production patent will let them maintain exclusivity without it being a patent on the drug itself?